Objective: Although endobronchial intubation during a bronchoscopic examination is useful for invasive procedures, it is not routine practice in Japan. The present study evaluated discomfort due to endobronchial intubation using fentanyl and midazolam sedation during bronchoscopy. Methods: Thirty-nine patients were enrolled prospectively from November 2014 to September 2015 at Okayama University Hospital. Fentanyl (20 µg) was administered to the patients just before endobronchial intubation, and fentanyl (10 µg) and midazolam (1 mg) were added as needed during the procedure. A questionnaire survey was administered 2 h after the examination. In the questionnaire, patient satisfaction was scored using a visual analog scale as follows: excellent (1 point), good (2 points), normal (3 points), uncomfortable (4 points) and very uncomfortable (5 points). An additional question ('Do you remember the bronchoscopic examination?') was also asked. Predefined parameters (blood pressure, heart rate, oxygen saturation and complications) were recorded. Results: The enrolled patients included 22 males and 17 females; their median age was 70 (range: 28-88) years. The patients received a mean dose of 47.9 µg of fentanyl (range: 30-90 µg) and 2.79 mg of midazolam (range: 1-7 mg). In total, 28 patients (71.7%) agreed to undergo a second bronchoscopic examination; the mean levels of discomfort and for the re-examination were 2.07 points each. About 41% of the patients remembered the bronchoscopic examination. No severe complications were reported. Conclusion: Endobronchial intubation using fentanyl and midazolam sedation during an invasive bronchoscopic procedure might be recommended. Clinical Trial Registration: UMIN000015578 in the UMIN Clinical Trials Registry
Introduction
According to a nationwide questionnaire survey conducted by the Japan Society for Respiratory Endoscopy (JSRE), endobronchial intubation is performed during bronchoscopic examination as a standard part of the procedure at only 13.0% of facilities (1) . The method is not necessary for routine bronchoscope practice, but it is extremely effective for invasive procedures such as the biopsy of hemorrhagic lesions. Sedation is widely used by pulmonary physicians for bronchoscopic examinations in the USA and Europe (2, 3) . The American College of Chest Physicians recommends a benzodiazepine and opiate combination because of good patient tolerance and the synergistic effect (4) . British Thoracic Society (BTS) guidelines for diagnostic flexible bronchoscopy in adults also recommend the use of benzodiazepines and/or opiates (5) . The main advantage of opioids over benzodiazepines for a bronchoscopic examination is their cough suppressive effect (6) (7) (8) . Benzodiazepine and/or opiate sedation is not routinely used for procedures in Japan; the sedative drugs used vary according to the preference of the physician.
Endobronchial intubation is usually used during bronchoscopic examinations of patients with a suspected high risk of complications such as hemoptysis. However, intubation often causes suffering. We previously showed that sedation with fentanyl and midazolam is safe and useful for bronchoscopic examination without endobronchial intubation (9) . Here, we prospectively evaluated the safety and patient discomfort levels during bronchoscopy with endobronchial intubation performed using combined fentanyl and midazolam sedation.
Patients and methods

Patient population and study design
Patients scheduled for a bronchoscopic examination were enrolled in this prospective study from November 2014 to September 2015 at Okayama University Hospital. A flow chart is shown in Fig. 1 . Eligible subjects were aged ≥20 years, had never undergone a bronchoscopic examination, had a performance status between 0 and 3, were of a suitable mental condition to take the questionnaire survey, and were not using an opioid at the time of the study. Patients subjected to an emergent bronchoscopic examination were excluded.
Fentanyl (20 µg) was administered intravenously to the patients just before endobronchial intubation; additional fentanyl (10 µg) and midazolam (1 mg) were given as needed. Naloxone (0.2 mg) and flumazenil (0.5 mg) were administered after the examination. A questionnaire survey, created by the JSRE Guidelines Development Committee, was administered 2 h after the examination. The questionnaire consisted of the following questions: (1) 'Did you suffer from the throat anesthesia?', (2) 'Did you suffer from the bronchoscopic examination?', (3) 'Did you have pain during the examination?', (4) 'How did you feel after the examination?', (5) 'What did you think about the examination time?' and (6) 'Would you undergo bronchoscopic re-examination if needed?' The responses were scored using a 5-point scale as follows: excellent (1 point), good (2 points), normal (3 points), uncomfortable (4 points) and very uncomfortable (5 points). Patients selected a score between 1 and 5 using a visual analog scale. An additional question ('Do you remember the bronchoscopic examination?') was asked, with a yes or no response. Predefined parameters, including blood pressure, heart rate, oxygen saturation and complications, were recorded. This study was approved by the Institutional Review Board of Okayama University Hospital (no. m04008) and was registered with the UMIN Clinical Trials Registry (UMIN000015578). Written informed consent was obtained from eligible patients who agreed to participate in the study.
Procedure
All bronchoscopic procedures were performed on an inpatient basis. A conventional flexible bronchoscope (P260F, BF-260, 1T260 or UC260F-OL8 bronchovideoscope; Olympus, Tokyo, Japan) was used with an uncuffed endobronchial intubation tube (Portex; Smith Medical, St. Paul, MN, USA). Pretreatment with 25 mg of hydroxyzine pamoate was applied by intramuscular injection. A total of 5 ml of 2% lidocaine was sprayed into the pharynx, and 15 ml of 2% lidocaine were administered through the channel during the procedure. Patients were monitored by electrocardiography, pulse oximetry and blood pressure monitoring every 5 min without the presence of an anesthesiologist.
Statistical analysis
We used an agreement rate (AR) for bronchoscopic re-examinations (≤2 points) with 45% midazolam based on previous clinical trial data (10) . We assumed that a 20% increase in AR was potentially useful because fentanyl is the most commonly used drug for bronchoscopy (6) (7) (8) . Thus, an AR of 65% indicated a potential benefit, and an AR of 45% was the lower limit of interest. The sample size was based on a Simon two-stage minimax design with a Type I error (α) of 0.05 and Type II error (β) of 0.2. Given these criteria, the target accrual was 30 Stage 1 patients. If fewer than 16 patients had ≤2 points, the protocol was determined to be ineffective. If ≥17 patients had ≤2 points, an additional 9 patients were enrolled in Stage 2. Finally, if ≥23 of the 39 patients had ≤2 points, the protocol was estimated to be effective.
Results
The patients' characteristics are listed in Table 1 . There were 22 males and 17 females, with a median age of 70 (range: 28-88) years. The bronchoscopic diagnoses were lung cancer (n = 23), sarcoidosis (n = 10), lymphoma (n = 2), infection (n = 1), sarcoma (n = 1), renal cell cancer (n = 1) and bile duct cancer (n = 1). The diameter of the bronchoscope was 4.0 mm in 11 cases, 4.9 mm in 11 cases and 5.9 mm in 17 cases. The diameter of the UC260F-OL8 bronchovideoscope for endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was 6.9 mm in 24 cases. The bronchoscopic procedures employed (transbronchial biopsy, bronchial brushing, bronchial washing, transbronchial lung biopsy and EBUS-TBNA) are shown in Table 1 .
Target lesions were classified according to distance from the hilum on CT image. When located in the inner and middle third ellipses and in the outer third ellipse, they were designated as central and peripheral parenchymal lungs, respectively (11) . In this study, 16 target lesions were located in peripheral lung and 15 were located in central lung.
The questionnaire survey results are shown in Table 2 . The mean discomfort level was 2.79 (range: 1-5) for throat anesthesia, 1.87 (range: 1-5) for the bronchoscopic examination, 1.05 (range: 1-2) for pain during the examination, 1.48 (range: 1-4) for patient comfort after the examination and 1.43 (range: 1-5) for the examination time. The acceptance level for re-examination was 2.07 (range: 1-4). In addition, 26 patients (71.7%) agreed to undergo a second bronchoscopic examination (≤2 points), which met the primary endpoint because 21 Stage 1 patients had ≤2 points and 28 patients had ≤2 points. The mean examination time was 32 min. The patients received a mean dose of 47.9 µg of fentanyl (range: 30-90 µg) and a mean dose of 2.79 mg of midazolam (range: 1-7 mg). Only 13 patients (41.0%) remembered the examination (Table 3) . Of the 24 patients who underwent EBUS-TBNA, the mean acceptance level for re-examination was 2.12 (range: 1-4). Microbial cultures of the wash collected through the TBNA needle lumen with sterile normal saline were negative in all 24 cases. No severe complications or cardiopulmonary failure cases were observed (Tables 3 and 4) .
Discussion
This is the first prospective trial to assess the tolerability of a bronchoscopic examination with endobronchial intubation using a combination of fentanyl and midazolam in Japan. In the Chiba Cancer Center's study (10), which evaluated the discomfort level for transbronchial biopsy and EBUS-TBNA without endobronchial intubation using midazolam alone, 45.5% of patients agreed to undergo a second bronchoscopic examination, and the mean evaluation level was 2.75 for re-examination acceptance based on a questionnaire survey. Compared with their study, both the rate (71.7%) and mean evaluation level (2.07) of acceptance for re-examination were better in our study. Our results indicate that the combination of midazolam and fentanyl might be useful despite the presence or absence of endobronchial intubation. In this study, endobronchial intubation was performed when a high risk of complications such as hemoptysis was suspected or when EBUS-TBNA procedure was planned. Meanwhile, when a low risk of complications was expected, we did not perform endobronchial intubation (9) . Discomfort level, complication and vital parameter in this study were similar in our previous report (9) . There was no pneumothorax patient in this study. The American College of Chest Physicians and BTS guidelines recommend diagnostic flexible bronchoscopy under conscious sedation (4, 5) . Bronchoscopy under conscious sedation with a combination of midazolam with fentanyl in this study could be safely performed and confirmed the previous study (12) . Conscious sedation may lead to avoid pneumothorax. A prospective study to compare midazolam alone with the combination might be of interest. A visual analog scale was used to evaluate each discomfort level using a questionnaire survey. Levels 1, 2, 3, 4 and 5 correspond to excellent, good, normal, uncomfortable and very uncomfortable, respectively. The parameters were monitored before and during the examination.
A previous report showed that EBUS-TBNA performed under moderate sedation with a combination of fentanyl and midazolam resulted in comparable diagnostic yield, major complication rate and patient tolerance values compared with those who received general anesthesia (13) . EBUS-TBNA with endobronchial intubation was performed in 24 patients in this post hoc analysis. The mean acceptance level for re-examination was 2.12 (range: 1-4), and no severe complications were encountered. A prospective evaluation of EBUS-TBNA using fentanyl and midazolam in Japan has not been reported. Microbial cultures of the wash obtained through the TBNA needle lumen were negative. Fujiwara et al. (14) reported that contamination by oral bacteria in punctured lymph nodes might cause severe infectious complications, including mediastinal abscesses and pericarditis, and no disagreement has been reported by other studies (15, 16) . Steinfort et al. reported that the prospective evaluation was undertaken in order to determine the incidence of bacteremia and infectious complications associated with EBUS-TBNA. Culture of needle washing was positive in 35% of all the patients, and all bacterial isolates were typical oropharyngeal commensal organisms (17) . Endobronchial intubation may be useful to avoid contamination by oropharyngeal commensal bacteria. A large-scale observational study based on clinical practice is needed to confirm these findings.
Endobronchial intubation for a bronchoscopic examination is clinically useful to biopsy hemorrhagic lesions, a bronchial occlusion with an endobronchial Watanabe spigot, and transbronchial biopsy and EBUS-TBNA approaches. The combination of fentanyl and midazolam for sedation during a bronchoscopic examination seemed to provide more comfort and was tolerated better than midazolam alone (9) . The present study confirmed the recommendation from BTS guidelines (5) . In order to change Japanese routine procedures, a large-scale study using a combination of fentanyl and midazolam during bronchoscopy is required. Our results in this study suggest a benefit of a combination of fentanyl and midazolam during bronchoscopic examinations regardless of endobronchial intubation. This is the first prospective trial to assess the tolerability of bronchoscopy using endobronchial intubation in Japan. Meanwhile, endobronchial intubation might be useful to avoid severe infectious complications. Prospective and randomized studies are needed to improve the levels of safety and patient satisfaction for invasive bronchoscopic procedures.
